PCM
MLYS icon

Pentwater Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Pentwater Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-80,000
Closed -$1.36M – 127
2023
Q2 		$1.36M Buy
80,000
+10,000
+14% +$149K 0.01% 101
2023
Q1 		$1.1M Buy
+70,000
New +$1.18M 0.01% 118

Other funds holding MLYS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Pentwater Capital Management's MLYS Position: Q3 2023 in Review

Pentwater Capital Management sold out of Mineralys Therapeutics (MLYS) in Q3 2023, closing a stake of 80,000 shares — an estimated $1.36M sold.

Pentwater Capital Management first reported a position in MLYS in Q1 2023 and held it in 2 quarters. The position peaked at $1.36M in Q2 2023. 77 funds tracked by Wall St. Rank hold MLYS as of Q3 2023.

  • Pentwater Capital Management reported no remaining Mineralys Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Pentwater Capital Management sold 80,000 Mineralys Therapeutics shares in Q3 2023, an estimated $1.36M.
  • Pentwater Capital Management first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 2 quarters.
  • Pentwater Capital Management's Mineralys Therapeutics position peaked at $1.36M in Q2 2023.
  • 77 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2023.

Based on Pentwater Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.